ArticleThe Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology2025
IREB2 Knockdown Alleviates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease by TLR4/NF-κB Signaling Inactivation.
Article in The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic liver diseases and is characterized by extensive deposition of fat in hepatocytes. This study aims to elucidate iron responsive element binding protein 2's (IREB2) role in highfat diet (HFD)-induced NAFLD and the regulatory mechanisms of the TLR4/NF-κB cascade. Materials and Methods: Male rats were fed an HFD to induce the NAFLD in vivo model. Changes in body weight and liver tissue weight were measured. Liver tissue damage and hepatic steatosis were monitored by hematoxylin-eosin staining in rats. Fat droplet size of rat liver tissue was detected by oil red O staining kit to evaluate fat deposition. Total cholesterol (TC), triglycerides (TG), alanine transaminase (ALT), Aspartate transaminase (AST), fatty acid synthase (FAS, and PPARα were detected by enzyme-linked immunosorbent assay (ELISA) kit and western blot. Interleukin-1-beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) were detected by ELISA. Finally, glucose tolerance and insulin sensitivity were measured by glucose analyzer. Results: IREB2 was highly expressed in the liver tissue of NAFLD rats. The body weight and liver tissue weight of rats with knockdown of IREB2 were lower than those fed HFD, and the liver tissue was severely damaged, serum ALT/AST activity, glucose, TG, and TC levels were increased. In addition, overexpressing IREB2 increased IL-1β, IL-6, and TNF-α, promoting HFD-induced metabolic disorders, hepatic steatosis, and inflammation. Knocking down IREB2 had the opposite effect. Blocking the TLR4/NF-κB cascade reversed the promoting effect of IREB2 on steatosis and inflammatory response. Conclusion: NAFLD treatment and prevention could benefit from IREB2, which may be closely related to TLR4/NF-κB signaling in lipid metabolism and glucose tolerance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.